Arpida Gains On Iclaprim Data From Second cSSSI Pivotal Trial

Arpida AG remains on track to file for marketing approval for the intravenous antibiotic iclaprim in the U.S. and Europe before the year-end, following positive topline data from a second pivotal trial of the compound in patients with complicated skin and skin structure infection (cSSSI). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)